IMS Health plans an initial public offering, according to a filing with the Securities and Exchange Commission. The firm collects and sells data and reports to pharmaceutical and biotechnology firms, consulting organizations, advertising agencies, and other organizations. Privacy advocates have expressed concern about physician and patient data, but IMS' filing reassured the SEC that the company remains committed to privacy and security.

Full Story:

Related Summaries